Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren's Disease

NCT07041099 is registered in ClinicalTrials.gov with Cullinan Therapeutics Inc. as lead sponsor.

NCT NCT07041099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07041099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren's Disease
Lead sponsor
Cullinan Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 1, 2025
Completion date
March 15, 2029
Enrollment
36 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

sjogren disease, sjogren's syndrome, sjögren